In the Red Section of this issue of the American Journal of Gastroenterology , well-known specialists in their respective fi elds present highlights from gastroenterology research in Spain. Th ese reports illustrate how well-organized network collaborations could impact the scientifi c literature worldwide, as these collaborations are positioned at the frontier of knowledge and could reveal innovative approaches to the diagnosis and treatment of patients with digestive diseases. Th ese achievements are especially notable, given that they occurred during a serious worldwide economic crisis that aff ected research in many countries, especially those that do not generally prioritize science ( 1, 2 ) .
Most of the successes presented here were obtained under the umbrella of two national organizations. One is the CIBERehd, an acronym of the Spanish name "Centro de Investigation Biomédica en Red para Enfermedades Hepáticas y Digestivas" or "Biomedical Research Networking Center Consortium in Hepatic and Digestive Diseases" in English. Th e CIBERehd ( http://www.ciberehd. org ) is part of a larger entity known as "CIBER", which has additional areas of interest focused on a variety of human diseases. Th e CIBER was initiated and organized by the National Institute of Health Carlos III ( http://www.eng.isciii.es ), in charge of coordinating Spanish biomedical research. Th e CIBERehd is a "virtual" center, combining the eff orts of the best research groups in gastroenterology and hepatology across the country, and it funds, awards, and prioritizes collaborative research among the groups.
Th e second organization may have even greater merit in this context, and is known as the Asociación Española de Gastro enterología (AEG) ( http://www.aegastro.es ), also known as the "Spanish Association of Gastroenterology" in English. Th e AEG has promoted important network research collaborations joining the eff orts of many clinical research groups of diff erent sizes and capacities. Many of these groups are not yet included in the CIBERehd, which limits their capacity for funding. Th e AEG has several working groups (Esophagus-Stomach-Duodenum, GI Oncology, Endoscopy, Neuro-gastroenterology and Motility, Infl ammatory Bowel Diseases, Pancreas and Biliary Tree) and platforms and collaborates closely with other scientifi c organizations, including the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) with its registries and methodological unit, as well as the Spanish Pancreatic Club. In just 10 years, CIBER investigators have published >7200 articles in the top medical journals, and almost 2600 of them were related to CIBERehd. Th e AEG groups have published almost 300 studies over the same period, fi ft y of which have been published in Th e American Journal of Gastroenterology ( 3, 4 ) .
One of the fi ve reports published in this special section illustrates two of the tools enabling this small miracle, the ENEIDA (Estudio Nacional en Enfermedad Infl amatoria intestinal sobre Determinantes genéticos y Ambientales) and the AEG-REDCap platforms. Adrian G. McNicholl and Javier P. Gisbert describe how "cost-zero" research in Spain combined with international competitive pressure created a strong collaboration of independent support networks through researcher associations and societies, and how this collaboration has become one of the most important contributors to Spanish Gastroenterology. ENEIDA, created by GETECCU, is a nationwide, hospital-based registry and biobank of Infl ammatory Bowel Disease patients from 100 Spanish hospitals. Th is database provides an infrastructure for the development of multicenter studies of all types. Th e impact and success of ENEIDA has grown exponentially and has become an inspiration for other European organizations replicating this model. Th e other major platform is the AEG-REDCap, created by AEG within a consortium agreement with Vanderbilt University ( 5 ). AEG-REDCap provides scientifi c methodological support and online data capture/management tools to over 50 projects, including more than 200 databases and 1300 researchers. Th e success of this initiative inspired participation by many European researchers in this local Spanish platform. Th e European Registry on Helicobacter pylori management is the best example of this success as well as the largest international project, with over 25,000 cases already registered.
In the pages that follow, Enrique Quintero and Antonio GimenoGarcía off er a perspective on colorectal cancer screening based on studies conducted in Europe in general, and Spain in particular. Much of that knowledge was again obtained within the collaborative network of the GI Oncology group of AEG. Th is AEG working group has effi ciently and successfully generated ongoing projects,
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including the EPICOLON (estudio de la EPIdemiologia del cáncer de COLON) I and II as well as COLONPREV (COLON PREVention study), which have already resulted in important reports. Th e COLONPREV project ( 6 ) will be the fi rst RCT to provide 10-year mortality data, comparing colonoscopy and biennial FIT, as screening methods for intermediate risk populations over the age of 50. On the basis of the local and regional studies summarized in their report, Quintero and Gimeno-García conclude that under conditions of universal access to our National public Health System and coming from a Spanish perspective, the current recommendations for colorectal cancer screening of fi rst-degree relatives of patients with colorectal cancer should be revised for individuals with only one index case in the family. In their view, the evidence currently supports that these patients should follow a similar screening strategy as those classifi ed within the average-risk population, and that fecal immunological tests (FIT) should be off ered as an alternative to colonoscopy screening in this population.
Enrique de Madaria reports another exciting outcome of network collaboration for the study of pancreatic diseases in Spain. He presents four clinical multicenter studies based on basic research addressing the eff ect of statins in experimental pancreatitis, and suggests a potential role for these drugs in improving the disease course as well as several outcomes. Th e EST-CPRE study, a retrospective analysis of consecutive patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) in four centers in Spain, found that patients consuming statins had a 70% lower risk of post-ERCP acute pancreatitis. Th is result prompted the initiation of a pan-European prospective cohort study involving centers from Spain, Italy, Finland, Croatia, Sweden, and Romania to confi rm these results with the STARK study ( STA tins and R is K of post-ERCP acute pancreatitis). Th e STAR-TREC trial is another collaborative study, involving centers from Spain, Peru, and Bolivia, aiming to investigate whether atorvastatin will be useful in the prevention of acute pancreatitis aft er ERCP. Finally, Madaria presents the SIMBA trial, ( SIM vastatin in the prevention of recurrent acute pancreatitis, a triple-B lind, r A ndomized controlled trial) designed to investigate the eff ectiveness of simvastatin (40 mg daily) in decreasing the incidence of new episodes of AP in recurrent cases. Th is multicenter, randomized, triple-blind, placebo-controlled trial is focused on adult patients with at least 2 episodes of AP. Fift een centers from Spain have joined SIMBA, and recruitment has already started ( 7 ) .
Th e European and especially the Spanish contribution to our understanding of Eosinofi lic Esophagitis (EoE), a relatively new diagnosis, has been notable over the last 5 years. Javier Molina and Alfredo Lucendo are two of the most important researchers in this area ( 8 ) . Th eir studies have been conducted in Spain, and are now being projected within the United European Gastroenterology (UEG) organization. Crucially, these studies have advanced the understanding that GERD and EoE are not mutually exclusive disorders, and that there is a clear EoE phenotype with complete remission on PPIs, with or without GERD. European studies have demonstrated that phenotypic, molecular, and mechanistic features cannot distinguish between patients with EoE that do or do not respond to PPI. Th erefore, Molina and Lucendo conclude that PPI therapy responders should be included within the spectrum of EoE, suggesting novel questions requiring investigation with new compounds such as vonoprazan, the fi rst agent of a new class of potassium-competitive acid blockers.
Th e last report comes from one of our most relevant investigators on functional disorders. Fermin Mearín provides a provocatively titled report on the specifi cally Spanish view of IBS. Fermín Mearin has conducted several studies within the AEG working group, and is one of the researchers most familiar with the perception of this disease by Spanish and European gastroenterologists ( 9 ) . Despite living in a Mediterranean country and consuming a Mediterranean diet, Spanish people are not "immune" to IBS. We appear to have similar IBS subtypes as patients from other parts of the world, with small diff erences relative to Northern European Countries and the USA. Mearin also points out that Spanish IBS patients seek medical attention more frequently than patients from other countries. Th is may be due to our public and open access universal health systems, and could have a tremendous impact on costs. Clearly, the regional IBS perspective described by Dr. Mearin will be crucial for an improved understanding of this disease, and will open areas of research for those interested in functional disorders.
Th ese are just some examples of the excellent research currently performed in Spain, and refl ected the experiences of hardworking doctors and scientists in harsh economic environments. One could imagine what they would accomplish under a better support from our national and regional institutions.
